Vascular endothelial growth factor promoter-based conditionally replicative adenoviruses for pan-carcinoma application.
Treatment of advanced lung cancer is one of the major challenges in current medicine because of the high morbidity and mortality of the disease. Advanced stage lung cancer is refractory to conventional therapies and has an extremely poor prognosis. Thus, new therapeutic approaches are needed. Lung tumor formation depends on angiogenesis in which the vascular endothelial growth factor (VEGF) produced by cancer cells plays a pivotal role. Neutralizing VEGF with a soluble VEGF receptor suppresses tumor growth; however, the anticancer effect with this therapy is weakened after the intratumoral vascular network is completed. In this study, we turned the expression of VEGF by tumors to therapeutic advantage using a conditionally replication-competent adenovirus (CRAd) in which the expression of E1 is controlled by the human VEGF promoter. This virus achieved good levels of viral replication in lung cancer cells and induced a substantial anticancer effect in vitro and in vivo. As a further enhancement, the cancer cell killing effect was improved with tropism modification of the virus to express the knob domain of Ad3, which improved infectivity for cancer cells. These VEGF promoter-based CRAds also showed a significant cell killing effect for various types of cancer lines other than lung cancer. Conversely, the VEGF promoter has low activity in normal tissues, and the CRAd caused no damage to normal bronchial epithelial cells. Since tumor-associated angiogenesis via VEGF signalling is common in many types of cancers, these CRAds may be applicable to a wide range of tumors. We concluded that VEGF promoter-based CRAds have the potential to be an effective strategy for cancer treatment.
Takayama
K
K
Department of Medicine, Division of Human Gene Therapy, The University of Alabama at Birmingham, Birmingham, AL, USA.
Reynolds
P N
PN
Adachi
Y
Y
Kaliberova
L
L
Uchino
J
J
Nakanishi
Y
Y
Curiel
D T
DT
D000256:Adenoviridae / Q000235:genetics* / Q000502:physiology; D001483:Base Sequence; D017931:DNA Primers; D015316:Genetic Therapy; D006801:Humans; D009369:Neoplasms / Q000628:therapy*; D011401:Promoter Regions, Genetic; D019076:Transgenes; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics*; D014779:Virus Replication
D017931:DNA Primers; D042461:Vascular Endothelial Growth Factor A